openPR Logo
Press release

Non Alcoholic Fatty Liver Disease Treatment Market Growth Trends, Key Players, Competitive Strategies and Forecasts to 2025

Non Alcoholic Fatty Liver Disease Treatment Market Growth

The report "Non Alcoholic Fatty Liver Disease Treatment Market - Global Industry Trend Analysis 2012 to 2016 and Forecast 2016 - 2025" gives complete assessment of the latest trends, challenges of market.

The objectives of this study are as follows:

• To define, describe, and forecast the "Non Alcoholic Fatty Liver Disease Treatment" market by type, application, component, delivery model, end user, and region
• To provide detailed information regarding major factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges)
• To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
• To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
• To forecast the market size of market segments with respect to the four key regions: North America, Europe, Asia, and the Rest of the World (RoW)
• To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies

Get Sample Copy Of This Report @ https://www.marketresearchreports.biz/sample/sample/12211

Fatty liver disease refers to the accumulation of fat (triglycerides,) in the liver. The liver cell contains fats, but the accumulation of excess fat can be a cause of concern and can lead to liver inflammation known as steatohepatitis.  The fatty liver can be caused by alcohol as well as can be non-alcohol.  Steatohepatitis can cause liver cirrhosis (fibrosis, scarring, and hardening of the liver). The cause of non-alcoholic fatty liver disease (NAFLD) is unknown. The nonalcoholic fatty liver disease (NAFLD) is one of the most common diseases in the United States. The prevalence of nonalcoholic fatty liver disease (NAFLD) is rising due to rise in prevalence of diabetes and obesity. According to National Health and Nutrition Examination survey, about 20-30% of the general population in the western world suffer from nonalcoholic fatty liver disease (NAFLD). The common symptoms include fatigue, weakness, weight loss and others. The diagnosis of NAFLD requires the combination of different tests such as blood test, ultrasound, CT scan, MRI scan, and liver biopsy.  The two types of Nonalcoholic fatty liver disease (NAFLD) includes simple fatty liver and Nonalcoholic Steatohepatitis (NASH). The simple fatty liver is a type of nonalcoholic fatty liver (NAFL), in which fat is deposited, but no inflammation or liver damage is observed. NASH is the inflammation of the liver due to excess fat deposit and can lead to liver damage and disease.

In 2014, according to World Health Organization (WHO), estimate about ~422 Mn of the adult population was suffering from diabetes as compared to the ~108 Mn in 1980. The worldwide prevalence of diabetes is rising with the overall prevalence of 4.7% in 1980 to 8.5% in 2014. Therefore, rising prevalence of diabetes and obesity is a major factor contributing to revenue growth of nonalcoholic fatty liver disease treatment market across the globe. Availability of expanded product line as major market players in the global nonalcoholic fatty liver disease treatment market are introducing innovative and expanded line products to retain market share, expansion in clinical trials will lead to product approvals and revenue generation. Manufacturers and organizations such as National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and National Institutes of Health (NIH) are involved research and development and are supporting research for various disease conditions. These are some of the factors boosting the growth of the nonalcoholic fatty liver disease treatment market
The global nonalcoholic fatty liver disease treatment market is segmented on basis of product type, end user and geography

Request For TOC @ https://www.marketresearchreports.biz/sample/toc/12211

Segment by Product Type
• Antioxidants
• Thiazolidinedione
• Biguanides
• Lipid lowering Agents
• FXR Receptor Agonist
• Others
Segment by Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Drug Stores
• Online Pharmacy
• Others
Global nonalcoholic fatty liver disease treatment market is segmented by product type and distribution channel. Based on the product type, the market is segmented into antioxidants, thiazolidinedione, biguanides, lipid lowering Agents, FXR receptor agonist and other medication used to treat nonalcoholic fatty liver disease. According to National Health and Nutrition Examination surveys conducted between 2009-2010, reported that prevalence of NASH is about 3% in general population in United States and about 25% in the obese individual. Thiazolidinedione and metformin are widely used for the Non-Alcoholic Liver Disease (NAFLD), thiazolidinedione and metformin are expected to gain higher share among other product types and will contribute in the revenue growth of global nonalcoholic fatty liver disease treatment market.

By Geography, the global nonalcoholic fatty liver disease treatment market is segmented into five broad regions viz.  North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. North America is estimated to lead the global nonalcoholic fatty liver disease treatment market due to increase in prevalence of diabetes and cardiovascular diseases in United States. Large number of manufacturers exist in the market, with large number of customer base. Asia Pacific market is also projected to experience high growth in the near future owing to factors such as, increase in healthcare expenditure, rising standard of living, lifestyle changes- attributed to better healthcare and awareness of the cost-effective treatment process with government grants and funding for acceleration in research and development activities.
Some of the major players in global nonalcoholic fatty liver disease treatment market Pfizer Inc., Hoffmann-La Roche Ltd., Daewoong Co., Ltd., Cardax, Inc., Merck & Co., Inc., Novartis AG, Gilead Sciences, Inc., AstraZeneca plc., Limerick BioPharma, Inc., GW Pharmaceuticals, Allergan, Plc., Takeda Pharmaceutical Company Ltd and others
MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.

The report provides the following information:
• Tailwinds and headwinds molding the market’s trajectory
• Market segments based on products, technology, and applications
• Prospects of each segment
• Overall current and possible future size of the market
• Growth pace of the market
• Competitive landscape and key players’ strategies
The main aim of the report is to:
• Enable key stakeholder’s in the market bet right on it
• Understand the opportunities and pitfalls awaiting them
• Assess the overall growth scope in the near term
• Strategize effectively with respect to production and distribution
MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.

Pre Book Report @ https://www.marketresearchreports.biz/checkout?rep_id=12211&licType=S

About Us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact Us

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Non Alcoholic Fatty Liver Disease Treatment Market Growth Trends, Key Players, Competitive Strategies and Forecasts to 2025 here

News-ID: 1470284 • Views:

More Releases for NAFL

According to DelveInsight, the Non Alcoholic Fatty Liver Disease Market in 7MM i …
DelveInsight's "Non Alcoholic Fatty Liver Disease Market" report provides a thorough comprehension of the Non Alcoholic Fatty Liver Disease, historical and forecasted epidemiology, and the Non Alcoholic Fatty Liver Disease market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Non Alcoholic Fatty Liver Disease market report also proffers an analysis of the current Non Alcoholic Fatty Liver Disease treatment algorithm/practice,
Rapid Increase in End-use Adoption to Boost Non Alcoholic Fatty Liver Disease Tr …
Fatty liver disease refers to the accumulation of fat (triglycerides,) in the liver. The liver cell contains fats, but the accumulation of excess fat can be a cause of concern and can lead to liver inflammation known as steatohepatitis. The fatty liver can be caused by alcohol as well as can be non-alcohol. Steatohepatitis can cause liver cirrhosis (fibrosis, scarring, and hardening of the liver). The cause of
Non Alcoholic Fatty Liver Disease Treatment Market 2019 by Top Key Players:Pfize …
Market Study Report, LLC’s, latest study on Non Alcoholic Fatty Liver Disease Treatment Market features a holistic view of the market size, market share, profit estimates, SWOT analysis and the regional landscape of the business. The report precisely expounds key challenges and future growth prospects of the market, while highlighting the current competitive scene and analyzes the expansion strategies adopted by leading market players. This report studies the Non Alcoholic Fatty
Non Alcoholic Fatty Liver Disease Treatment Market to Observe Strong Development …
Fatty liver disease refers to the accumulation of fat (triglycerides,) in the liver. The liver cell contains fats, but the accumulation of excess fat can be a cause of concern and can lead to liver inflammation known as steatohepatitis. The fatty liver can be caused by alcohol as well as can be non-alcohol. Steatohepatitis can cause liver cirrhosis (fibrosis, scarring, and hardening of the liver). The cause of
FIATA, SCLG join Second Annual Middle East Logistics Awards as Industry Support …
Top logistics industry associations endorse MELA 2007 Awards June 28, 2007, Dubai, UAE: As the nomination phase of the Second Annual Middle East Logistics Awards (MELA) 2007 is gaining momentum, some of the leading logistics bodies have announced their support for the prestigious event. International Federation of Freight Forwarders Associations (FIATA) and Supply Chain and Logistics Group (SCLG) have joined MELA as Industry Support Patrons. Manfred F Boes, President, FIATA,
The Second Annual Middle East Logistics Awards (MELA) 2007
Nominations for MELA 2007 Awards kick-start Middle East’s premier logistics awards will recognise stellar performers the second time around June 17, 2007, Dubai, UAE: The MELA Management Office has initiated the nomination process for the Second Annual Middle East Logistics Awards (MELA) 2007, as part of its endeavour to benchmark performance excellence in the Middle East logistics industry and to recognise the top performers for their out-of-the-box achievements. MELA 2007 nominations are